Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

With its unique target discovery platforms, PandaOmics and Chemistry42, AI company Insilico is transforming the world of research and development. Deep learning in biopharma has come of age.

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

For further information, please refer to www.harbourbiomed.com. Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry ...

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems.

the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, and Insilico ...